Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention. A Call for Completion of Randomized Clinical Trials A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory

Journal of the American College of Cardiology

Volumn 53, Issue 21, 2009, Pages 2014-2018

  O'Gara, Patrick T ^a   Messe, Steven R ^a   Tuzcu, E Murat ^a   Catha, Gloria ^a   Ring, John C ^a  

^a NONE

Author keywords

ACCF Expert Consensus Documents; aneurysm; anticoagulation; antiplatelet agents; patent foramen ovale; stroke; surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; WARFARIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEEP VEIN THROMBOSIS; DEVICE THERAPY; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART CYCLE; HUMAN; MEDICAL SOCIETY; MORBIDITY; OPERATING ROOM PERSONNEL; PATENT FORAMEN OVALE; PATIENT CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

EQUIPMENT DESIGN; FORAMEN OVALE, PATENT; HEART CATHETERIZATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; SOCIETIES, MEDICAL; UNITED STATES;

EID: 65649149462     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.001     Document Type: Review

References (38)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Goldstein L.B., Adams R., Alberts M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in Circulation. 2006;114:e617]. Circulation 113 (2006) e873-e923
3. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. Circulation 113 (2006) e409-e449
4. Sacco R.L., Elllenberg J.H., Mohr J.P., et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 25 (1989) 382-390
5. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
6. Grau A.J., Weimar C., Buggle F., et al. Risk factors, outcome, and treatment subtypes of ischemic stroke: the German stroke data bank. Stroke 32 (2001) 2559-2566
7. Lee B.C., Hwang S.H., Jung S., et al. The Hallym Stroke Registry: a web-based stroke data bank with an analysis of 1,654 consecutive patients with acute stroke. Eur Neurol 54 (2005) 81-88
8. Hagen P.T., Scholz D.G., and Edwards W.D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59 (1984) 17-20
9. Di Tullio M.R., Sacco R.L., Sciacca R.R., et al. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 49 (2007) 797-802
10. Meissner I., Khandheria B.K., Heit J.A., et al. Patent foramen ovale: innocent or guilty?. Evidence from a prospective population-based study. J Am Coll Cardiol 47 (2006) 440-445
11. Attaran R.R., Ata I., Kudithipudi V., et al. Protocol for optimal detection and exclusion of a patent foramen ovale using transthoracic echocardiography with agitated saline microbubbles. Echocardiography 23 (2006) 616-622
12. Mügge A., Daniel W.G., Angermann C., et al. Atrial septal aneurysm in adult patients: a multicenter study using transthoracic and transesophageal echocardiography. Circulation 91 (1995) 2785-2792
13. Srivastava T.N., and Payment M.F. Images in clinical medicine: paradoxical embolism-thrombus in transit through a patent foramen ovale. N Engl J Med 337 (1997) 681
14. Lethen H., Flachskampf F.A., Schneider R., et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 80 (1997) 1066-1069
15. Stöllberger C., Slany J., Schuster I., et al. The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism [published correction appears in Ann Intern Med. 1994;120:347]. Ann Intern Med 119 (1993) 461-465
16. Homma S., and Sacco R.L. Contemporary reviews in cardiovascular medicine: patent foramen ovale and stroke. Circulation 112 (2005) 1063-1072
17. Halperin J.L., and Fuster V. Patent foramen ovale and recurrent stroke: another paradoxical twist. Circulation 105 (2002) 2580-2582
18. Lamy C., Giannesini C., Zuber M., et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Stroke 33 (2002) 706-711
19. Homma S., Sacco R.L., Di Tullio M.R., et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale In Cryptogenic Stroke Study. Circulation 105 (2002) 2625-2631
20. Handke M., Harloff A., Olschewski M., et al. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 357 (2007) 2262-2268
21. Mas J.L., Arquizan C., Lamy C., et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345 (2001) 1740-1746
22. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet 368 (2006) 350-352
23. Homma S., DiTullio M.R., Sacco R.L., et al. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke 35 (2004) 2145-2149
24. Bogousslavsky J., Garazi S., Jeanrenaud X., et al. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study: Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 46 (1996) 1301-1305
25. Cujec B., Mainra R., and Johnson D.H. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 15 (1999) 57-64
26. Khairy P., O'Donnell C.P., and Landzberg M.J. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 139 (2003) 753-760
27. Salem D.N., O'Gara P.T., Madias C., et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 suppl (2008) 593S-629S
28. Maisel W.H., and Laskey W.K. Patent foramen ovale closure devices: moving beyond equipoise. JAMA 294 (2005) 366-369
29. Flachskampf F.A., and Daniel W.G. Closure of patent foramen ovale: is the case really closed as well?. Heart 91 (2005) 449-450
30. Dalen J.E. Are patients with a patent foramen ovale at increased risk of stroke?. A billion dollar question. Am J Med 120 (2007) 472-474
31. Opotowsky A.R., Landzberg M.J., Kimmel S.E., and Webb G.D. Trends in the use of percutaneous closure of patent foramen oval and atrial septal defect in adults, 1998-2004. JAMA 299 (2008) 521-522
32. Information for Physicians and Patients on the Withdrawal of Two Humanitarian Device Exemptions (HDEs) for Patent Foramen Ovale (PFO) Occluders. US Food and Drug Administration Web site (2006). http://www.fda.gov/cdrh/ode/h000007-h990011withdraw.html Accessed January 14, 2008
33. RESPECT: Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment Web page. http://www.strokecenter.org/trials/trialDetail.aspx?tid=482&search_s tring=PFO Accessed January 6, 2009
34. CLOSURE 1: Evaluation of the STARFlex Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO) (2006). http://www.clinicaltrials.gov/ct2/show/NCT00201461?term=PFO+AND+stroke &rank=5 Accessed March 20, 2009
35. GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients (Gore REDUCE) (2006). http://www.clinicaltrials.gov/ct2/show/NCT00738894?term=NCT00738894& rank=1 Accessed March 20, 2009
36. Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (CLOSE) (2006). http://www.clinicaltrials.gov/ct2/show/NCT00562289?term=PFO+AND+stroke &rank=4 Accessed January 6, 2009
37. PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism (2006). http://www.clinicaltrials.gov/ct2/show/NCT00166257?term=PFO+AND+stroke &rank=8 Accessed March 20, 2009
38. Slottow T.L., Steinberg D.H., and Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 116 (2007) 677-682